Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.


Journal

World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716

Informations de publication

Date de publication:
Sep 2023
Historique:
received: 22 03 2023
accepted: 01 07 2023
medline: 31 8 2023
pubmed: 22 7 2023
entrez: 22 7 2023
Statut: ppublish

Résumé

Cytology and cystoscopy, the current gold standard for diagnosing urothelial carcinomas, have limits: cytology has high interobserver variability with moderate or not optimal sensitivity (particularly for low-grade tumors); while cystoscopy is expensive, invasive, and operator dependent. The VISIOCYT1 study assessed the benefit of VisioCyt VISIOCYT1 was a French prospective clinical trial conducted in 14 centers. The trial enrolled adults undergoing endoscopy for suspected bladder cancer or to explore the lower urinary tract. Participants were allocated either Group 1: with bladder cancer, i.e., with positive cystoscopy or with negative cystoscopy but positive cytology, or Group 2: without bladder cancer. Before cystoscopy and histopathology, slides were prepared for cytology and the VisioCyt Between October 2017 and December 2019, 391 participants (170 in Group 1 and 149 in Group 2) were enrolled. VisioCyt VisioCyt

Identifiants

pubmed: 37480491
doi: 10.1007/s00345-023-04519-4
pii: 10.1007/s00345-023-04519-4
pmc: PMC10465399
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2381-2388

Informations de copyright

© 2023. The Author(s).

Références

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK et al (2020) Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 18:329–354
doi: 10.6004/jnccn.2020.0011 pubmed: 32135513
Reid MD, Osunkoya AO, Siddiqui MT, Looney SW (2012) Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol 5:882–891
pubmed: 23119105 pmcid: 3484494
Yafi FA, Brimo F, Steinberg J, Aprikian AG, Tanguay S, Kassouf W (2015) Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urol Oncol 33(66):e25-31
Oliveira MC, Caires HR, Oliveira MJ, Fraga A, Vasconcelos MH, Ribeiro R (2020) Urinary biomarkers in bladder cancer: Where do we stand and potential role of extracellular vesicles. Cancers (Basel) 12(6):1400
doi: 10.3390/cancers12061400 pubmed: 32485907 pmcid: 7352974
Soria F, D’Andrea D, Pohar K, Shariat SF, Lotan Y (2018) Diagnostic, prognostic and surveillance urinary markers in nonmuscle invasive bladder cancer: any role in clinical practice? Curr Opin Urol 28:577–583
doi: 10.1097/MOU.0000000000000545 pubmed: 30157039
Soubra A, Risk MC (2015) Diagnostics techniques in nonmuscle invasive bladder cancer. Indian J Urol 31:283–288
doi: 10.4103/0970-1591.166449 pubmed: 26604438 pmcid: 4626911
Burger M, Kamat AM, McConkey D (2021) Does variant histology change management of non-muscle-invasive bladder cancer? Eur Urol Oncol 4:510–514
doi: 10.1016/j.euo.2019.06.012 pubmed: 31395481
Chen J, Remulla D, Nguyen JH, Aastha D, Liu Y, Dasgupta P et al (2019) Current status of artificial intelligence applications in urology and their potential to influence clinical practice. BJU Int 124(4):567–577
doi: 10.1111/bju.14852 pubmed: 31219658
Checcucci E, Autorino R, Cacciamani GE, Amparore D, De Cillis S, Piana A et al (2020) Artificial intelligence and neural networks in urology: current clinical applications. Minerva Urol Nefrol 72:49–57
doi: 10.23736/S0393-2249.19.03613-0 pubmed: 31833725
Hosein S, Reitblat CR, Cone EB, Trinh QD (2020) Clinical applications of artificial intelligence in urologic oncology. Curr Opin Urol 30:748–753
doi: 10.1097/MOU.0000000000000819 pubmed: 32941255
Lebret T, Pignot G, Colombel M, Guy L, Rebillard X, Savareux L et al (2021) Artificial intelligence to improve cytology performances in bladder carcinoma detection: results of the VisioCyt test. BJU Int 129(3):356–363
doi: 10.1111/bju.15382 pubmed: 33751774
Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DF et al (2016) The paris system for reporting urinary cytology: the quest to develop a standardized terminology. Acta Cytol 60:185–197
doi: 10.1159/000446270 pubmed: 27318895
Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours. John Wiley & Sons
Matulewicz RS, Steinberg GD (2020) Non-muscle-invasive Bladder cancer: overview and contemporary treatment landscape of neoadjuvant chemoablative therapies. Rev Urol 22:43–51
pubmed: 32760227 pmcid: 7393683
Ikeda A, Nosato H, Kochi Y, Kojima T, Kawai K, Sakanashi H et al (2020) Support system of cystoscopic diagnosis for bladder cancer based on artificial intelligence. J Endourol 34:352–358
doi: 10.1089/end.2019.0509 pubmed: 31808367 pmcid: 7099426
Kufukihara R, Kikuchi E, Shigeta K, Ogihara K, Arita Y, Akita H et al (2022) Diagnostic performance of the vesical imaging-reporting and data system for detecting muscle-invasive bladder cancer in real clinical settings: Comparison with diagnostic cystoscopy. Urol Oncol 40:61 (e1-e8)
doi: 10.1016/j.urolonc.2021.07.005
Shah M, Naik N, Somani BK, Hameed BMZ (2020) Artificial intelligence (AI) in urology-current use and future directions: an iTRUE study. Turk J Urol 46:S27–S39
doi: 10.5152/tud.2020.20117 pubmed: 32479253 pmcid: 7731952
Gosnell ME, Polikarpov DM, Goldys EM, Zvyagin AV, Gillatt DA (2018) Computer-assisted cystoscopy diagnosis of bladder cancer. Urol Oncol 36:8.e9-8.e15
doi: 10.1016/j.urolonc.2017.08.026 pubmed: 28958822
Ikeda A, Nosato H, Kochi Y, Negoro H, Kojima T, Sakanashi H et al (2021) Cystoscopic imaging for bladder cancer detection based on stepwise organic transfer learning with a pretrained convolutional neural network. J Endourol 35:1030–1035
doi: 10.1089/end.2020.0919 pubmed: 33148020
Lorencin I, Andelic N, Spanjol J, Car Z (2020) Using multi-layer perceptron with Laplacian edge detector for bladder cancer diagnosis. Artif Intell Med 102:101746
doi: 10.1016/j.artmed.2019.101746 pubmed: 31980088
Sokolov I, Dokukin ME, Kalaparthi V, Miljkovic M, Wang A, Seigne JD et al (2018) Noninvasive diagnostic imaging using machine-learning analysis of nanoresolution images of cell surfaces: detection of bladder cancer. Proc Natl Acad Sci USA 115:12920–12925
doi: 10.1073/pnas.1816459115 pubmed: 30509988 pmcid: 6304950
Muralidaran C, Dey P, Nijhawan R, Kakkar N (2015) Artificial neural network in diagnosis of urothelial cell carcinoma in urine cytology. Diagn Cytopathol 43:443–449
doi: 10.1002/dc.23244 pubmed: 25605418
Sanghvi AB, Allen EZ, Callenberg KM, Pantanowitz L (2019) Performance of an artificial intelligence algorithm for reporting urine cytopathology. Cancer Cytopathol 127:658–666
doi: 10.1002/cncy.22176 pubmed: 31412169
Vaickus LJ, Suriawinata AA, Wei JW, Liu X (2019) Automating the Paris System for urine cytopathology—a hybrid deep-learning and morphometric approach. Cancer Cytopathol 127:98–115
doi: 10.1002/cncy.22099 pubmed: 30702803
Koss LG, Sherman AB (1984) Image analysis of cells in the sediment of voided urine. Monogr Clin Cytol 9:148–162
doi: 10.1159/000409906 pubmed: 6493237
McCroskey Z, Pambuccian SE, Kleitherms S, Antic T, Cohen MB, Barkan GA et al (2015) Accuracy and interobserver variability of the cytologic diagnosis of low-grade urothelial carcinoma in instrumented urinary tract cytology specimens. Am J Clin Pathol 144:902–908
doi: 10.1309/AJCPE1O9YKMRSQKG pubmed: 26572997

Auteurs

Thierry Lebret (T)

Urology Department, Foch Hospital, Suresnes, France.

Xavier Paoletti (X)

Institut Curie, Saint Cloud, France.
Université Versailles Saint-Quentin, Université Paris-Saclay, Saint Cloud, France.

Geraldine Pignot (G)

Urology Department, Institut Paoli-Calmettes, Marseille, France.

Mathieu Roumiguié (M)

Urology Department, Centre Hospitalier Universitaire (CHU) Rangueil, IUCT Oncopole, Toulouse, France.

Marc Colombel (M)

Urology Department, Hôpital Edouard Herriot, Lyon, France.

Laurent Savareux (L)

Urology Auvergne Centre, Clinique de la Chataigneraie, Beaumont, France.

Grégory Verhoest (G)

Urology Department, CHU Pontchaillou, Rennes, France.

Laurent Guy (L)

Urology Department of Urology, CHU Gabriel Montpied, Clermont-Ferrand, France.

Jérome Rigaud (J)

Urology Department, CHU Hôtel-Dieu, Nantes, France.

Stéphane De Vergie (S)

Urology Department, CHU Hôtel-Dieu, Nantes, France.

Grégoire Poinas (G)

Urology Department, Clinique Beausoleil, Montpellier, France.

Stéphane Droupy (S)

Urology Department, CHU Caremeau, Nîmes, France.

François Kleinclauss (F)

Urology Department, CHU Besançon, Besançon, France.

Monique Courtade-Saïdi (M)

Pathology and Cytology Department, CHU Toulouse, IUCT Oncopole, Toulouse, France.

Eric Piaton (E)

Centre de Pathologie Est, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Bron, France.

Camelia Radulescu (C)

Service d'Anatomie et Cytologie Pathologiques, Hôpital Foch, Suresnes, France.

Nathalie Rioux-Leclercq (N)

Department of Pathology, CHU Pontchaillou, Rennes, France.

Christine Kandel-Aznar (C)

Laboratoire d'Anatomie et Cytologie Pathologique, CHU Hôtel Dieu, Nantes, France.

Karine Renaudin (K)

Department of Pathology, CHU Hôtel Dieu, Nantes, France.
Centre de Recherche en Transplantation et en Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France.

Béatrix Cochand-Priollet (B)

Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France.

Yves Allory (Y)

Department of Pathology, Institut Curie, Saint-Cloud, France.
Institut Curie, PSL Research University, CNRS, UMR144, Equipe Labellisée Ligue Contre le Cancer, Paris, France.

Sébastien Nivet (S)

VitaDX International, Rennes, France. sebastien@vitadx.com.

Morgan Rouprêt (M)

Urology Department, GRC n°5, Predictive ONCO-URO, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH